The American Cancer Society released new colorectal cancer screening guidelines that include Exact Sciences Corp.'s (Nasdaq: EXAS) stool sample testing technology. The stock price surged $1.25 to $3.34.
Exact Sciences Technology Included In Cancer Screening
March 06, 2008 at 12:32 PM EST